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Influenza virus infections affect millions of people annually. Current available vaccines provide varying rates of protection.
There is a knowledge gap on how the nasal microbiota, particularly established pneumococcal colonization, shapes the
response to influenza vaccination. In this study, we inoculated healthy adults with live S. pneumoniae and vaccinated
them three days later with either TIV or LAIV. Vaccine-induced immune responses were assessed in nose, blood and
lung. Nasal pneumococcal colonization had no impact upon TIV-induced antibody responses to influenza, which
manifested in all compartments. However, experimentally-induced pneumococcal colonization dampened LAIV-mediated
mucosal antibody responses, primarily IgA in the nose and IgG in the lung. Pulmonary influenza-specific cellular
responses were more apparent in the LAIV group compared to either TIV or an unvaccinated group. These results
indicate that TIV and LAIV elicit differential immunity to adults and that LAIV immunogenicity is diminished by the nasal
presence of S. pneumoniae. Therefore, nasopharyngeal pneumococcal colonization may affect LAIV efficacy.
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Influenza virus infections affect millions of people annually. Current available vaccines provide 
varying rates of protection. There is a knowledge gap on how the nasal microbiota, particularly 
established pneumococcal colonization, shapes the response to influenza vaccination. In this 
study, we inoculated healthy adults with live S. pneumoniae and vaccinated them three days 
later with either TIV or LAIV. Vaccine-induced immune responses were assessed in nose, 
blood and lung. Nasal pneumococcal colonization had no impact upon TIV-induced antibody 
responses to influenza, which manifested in all compartments. However, experimentally 
induced pneumococcal colonization dampened LAIV-mediated mucosal antibody responses, 
primarily IgA in the nose and IgG in the lung. Pulmonary influenza-specific cellular responses 
were more apparent in the LAIV group compared to either TIV or an unvaccinated group. 
These results indicate that TIV and LAIV elicit differential immunity to adults and that LAIV 
immunogenicity is diminished by the nasal presence of S. pneumoniae. Therefore, 
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Each year, 5–15% of the world's population will suffer from an influenza infection, with 1 
up to 5 million cases of severe disease and 500,000 deaths (1). Influenza viruses have the 2 
ability to mutate and hence escape immune defence mechanisms, necessitating annual 3 
vaccine updates.  These vaccines include the tetravalent inactivated influenza vaccine (TIV) 4 
(2), which is given intramuscularly, and the live attenuated influenza vaccine (LAIV) (3), which 5 
is administered intranasally. The route of vaccination can trigger distinct immune mechanisms 6 
and pathways of protection. For example, TIV is given as an intramuscular injection and 7 
induces neutralizing antibodies to strain-specific glycoproteins hemagglutinin (HA) and 8 
neuraminidase (NA) (4). By comparison, LAIV is intranasally administered as a cold-adapted 9 
vaccine that replicates only in the nasopharynx and mimics natural infection (5). Nasal 10 
replication leads to recognition of its pathogen-associated molecular patterns (PAMPs) by host 11 
pattern recognition receptors (PRRs), which initiates a cascade of cellular immune responses 12 
(6). In mice, LAIV vaccination increases the frequency of CD4+ and CD8+ T cells in the lung 13 
and cytokine production upon influenza re-stimulation compared to vaccination with the 14 
inactivated virus or no vaccine administration (7-10). Moreover, LAIV seeds the murine lung 15 
with both CD4+ tissue resident memory (TRM) and virus-specific CD8+ T cells. TRM have been 16 
shown to provide long-term cross-strain protection against influenza (7).  In humans, the 17 
immune responses elicited by LAIV have been found to provide broader clinical protection in 18 
children compared to the inactivated influenza vaccines (IIVs) (11). However, the detailed 19 
immunological mechanisms of this remain incompletely understood. 20 
Influenza vaccines are re-formulated annually to represent circulating strains, but 21 
genomic changes over time (antigenic drift) reduce effectiveness (12).  Estimates from the 22 
World Health Organization (WHO) suggest that influenza vaccines effectiveness rarely 23 
exceeds 60% and has fallen below 30% in some years (13, 14). Poor effectiveness of LAIV 24 
among 2 to 17-year-olds in 2014 and 2015 led to the Centre for Disease Control (CDC) 25 
recommending its temporary exclusion from the US national childhood influenza immunization 26 
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programme during the subsequent two seasons (15). From 2018, no such recommendations 27 
have been made. Many underlying causes for this variation have been suggested, including: 28 
poor matching with circulating strains (12, 16), differential ability of some LAIV types to induce 29 
immunity (in particular against H1N1 strains (15),  and the microbial community composition at 30 
times of LAIV administration (17).  31 
Despite several reports about the microbiota and its impact on vaccination responses 32 
(18-21), including responses to influenza vaccine (20, 22), it remains unclear how the 33 
microbiome affects LAIV immunogenicity. In murine models, a prior exposure to S. 34 
pneumoniae (Spn) alters the anti-viral B cell responses during co-infection with wild-type 35 
influenza virus, potentially compromising long-term antiviral antibody-mediated immunity (23). 36 
Colonization of the nasopharynx with pneumococcus is very common during childhood, with 37 
a point prevalence of 50% of infants in resource-rich settings and up to 90% in low and middle 38 
income countries (24). A significant interaction between Spn colonization and influenza 39 
vaccination could profoundly impact the utility of vaccination, especially amongst the poorest 40 
groups of the world. 41 
We used an experimental human pneumococcal challenge (EHPC) model (25) to 42 
experimentally colonize adults with pneumococcus, who three days later received either LAIV 43 
(nasal) or TIV (intramuscular). We showed that in humans, LAIV elicits immune responses 44 
primarily at mucosal sites- the nose and lung. Interestingly, experimentally induced 45 
pneumococcal colonization impacted on LAIV immunogenicity, dampening the LAIV-mediated 46 
nasal and lung immune responses.  47 
RESULTS 48 
We conducted a double-blind randomised controlled clinical trial (26) in which healthy 49 
adults (18 to 48 years of age) were vaccinated with either TIV (n=90) or LAIV (n=80) three 50 
days after intranasal challenge with live S. pneumoniae (Figure 1A). To assess and compare 51 
the immune responses elicited by influenza vaccination, we analysed a series of samples in a 52 
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subset of 40 TIV and 80 LAIV vaccinated subjects. Mucosal samples, including nasal wash, 53 
nasal scrapes (epithelial and immune cells), nasal lining fluid and bronchoalveolar lavage 54 
(BAL), as well as serum samples, were collected from the two experimental groups and 55 
stratified according to vaccination and pneumococcal carriage status: 1) TIV vaccinated non-56 
Spn colonized (TIV/Spn-, n= 21), 2) TIV vaccinated Spn-colonized (TIV/Spn+, n= 19), 3) LAIV 57 
vaccinated non-Spn colonized (LAIV/Spn-, n= 37) and 4) LAIV vaccinated Spn-colonized 58 
(LAIV/Spn+, n= 43). For the assessment of lung immune responses, we included a non-59 
vaccinated cohort as control (n=20, 10 Spn- and 10 Spn+), since we were only able to sample 60 
the human lung post challenge/vaccination and not at baseline.  61 
Spn colonization prevents an acute nasal pro-inflammatory response upon LAIV 62 
administration 63 
Vaccine-induced inflammatory responses in the nasal mucosa were assessed by 64 
measuring levels of 30 cytokines in the nasal fluid at baseline, day -1 (2 days post Spn 65 
challenge but a day before vaccination) and at days 3, 6 and 24 post vaccination. LAIV 66 
administration induced a mild pro-inflammatory response, which resembled TIV based on 67 
similarity analysis (Figure 1B). In particular, only IP-10 and TNF-α were significantly increased 68 
(p < 0.05 by Wilcoxon test with Benjamini-Hochberg for multiple testing correction) at 3 days 69 
post LAIV. At day 6, levels of TNF-α remained increased compared to pre-challenge baseline 70 
(D-8 time point), and levels of 4 more cytokines (IL-1b, IL12, IL15 and IL-2R) had a transient 71 
induction at this time-point (Figure 1C). No other cytokine was significantly induced in either 72 
LAIV or TIV group at any timepoint. 73 
To investigate whether colonization of the nasopharynx with S. pneumoniae prior to 74 
transient LAIV infection would alter the LAIV-mediated immunogenicity, we stratified the 75 
groups according to volunteers’ colonization status and assessed the cytokines profile in the 76 
four experimental groups. LAIV induced a transient but robust pro-inflammatory response only 77 
in the absence of nasal pneumococcal colonization (Figure 1D). In particular, MIP-1, MIP-78 
1β, IFN-, IFN-, IP-10 and TNF- were significantly increased from pre-challenge baseline 79 
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at 3 days post LAIV in the non-colonized group (Figure 1E). At 6 days post LAIV, 21 out of 30 80 
measured cytokines were significantly increased in this group (Figure 1E). No other cytokine 81 
was significantly induced in any of the 4 groups at any timepoint.  82 
 83 
LAIV increases the frequency of influenza-specific TNF- and IFN-γ producing CD4+ 84 
and TRM CD4+ T cells in the lung 85 
Data from animal models suggest that LAIV, but not TIV, induces protective cellular 86 
responses in the lung (27, 28). To assess influenza vaccination-induced cellular responses in 87 
the human lung, bronchoalveolar lavage (BAL) cells were stimulated with influenza antigens. 88 
T cell subsets (CD4+, CD8+ and TCR-γδ+) were immunophenotyped and cytokine production 89 
was measured by intracellular cytokine staining in order to determine the frequency of IFN-, 90 
IL-17A and TNF--producing, influenza-specific T cells (Supplemental Figure 1). Frequencies 91 
of total CD4+, CD8+ and TCR-δ+ T cells were not affected by vaccination status (Supplemental 92 
Figure 2). Furthermore, we investigated the presence of tissue-resident memory T cell 93 
responses to influenza, using the extracellular markers CD69, CD103 and CD49a. As over 94 
1/3 of CD4+ CD69+ cells, commonly defined as TRM (29), did not express the additional 95 
resident memory markers CD103 and CD49a, we defined TRM only as CD69+ (Supplemental 96 
Figure 3). In contrast, nearly all CD8+CD69+ cells also expressed CD103 and CD49a. 97 
CD4+ TNF- production upon influenza stimulation was observed in both TIV and LAIV 98 
recipients regardless of colonization status, but not in unvaccinated individuals, (Figure 2A-99 
B). However, levels of influenza-specific TNF- were significantly increased in the LAIV/Spn- 100 
group compared to the unvaccinated group (median 2.6-fold increase, p = 0.015) (Figure 2B).  101 
Following stimulation with influenza antigens, CD4+ TRM T cells produced TNF- in all 102 
vaccinated groups but not in the unvaccinated group (Figure 2C). The induction of TNF- 103 
producing CD4+ TRM following stimulation did not significantly differ between TIV and LAIV, 104 
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but it was more pronounced in the LAIV group, in both the Spn- and Spn+ groups compared 105 
to the unvaccinated group (7.7-fold change, p=0.004 and 6.5-fold change, p=0.024 to 106 
unvaccinated, respectively) (Figure 2D). 107 
We also assessed IFN- production by total CD4+ and TRM CD4+ T cells residing in the 108 
human lung. IFN- production by total CD4+ T cells was observed in all groups upon 109 
stimulation, including the unvaccinated group (Figure 2E). The levels of IFN- producing CD4+ 110 
T cells were not different when comparing vaccinated and unvaccinated groups. The induction 111 
of IFN-γ producing CD4+ TRM T cells, however, was greater in the LAIV vaccinated group 112 
(Figure 2G). In contrast to total CD4+ T cells, stimulation of TRMs of unvaccinated individuals 113 
did not elicit an IFN- response (Figure 2G).  114 
Furthermore, the proportion of IL-17A producing CD4+ T cells or CD4+ TRM T cells was 115 
not affected by vaccination with either TIV or LAIV (Supplemental Figure 4A-B). The frequency 116 
of regulatory CD4+ T cells (T-regs) was also measured in the lung, with such cells showing 117 
increased levels in BAL samples of LAIV/ Spn- compared to unvaccinated individuals (mean 118 
1.5-fold increase) (p = 0.039) (Supplemental Figure 5). 119 
 120 
LAIV increases the frequency of influenza-specific TNF- producing CD8+ and TRM 121 
CD8+ T cells in the lungs 122 
In vitro re-stimulation with influenza induced increased production of TNF-α by CD8+ T 123 
cells in LAIV but not TIV or unvaccinated group (Figure 3). When volunteers were stratified 124 
based on colonization status, LAIV/Spn- had a median 2.3-fold increase of TNF-α producing 125 
CD8+T cells post stimulation compared to the non-stimulated condition (p=0.03). LAIV/Spn+ 126 
group had a similar induction on this type of cellular response (median 1.9-fold increase, 127 
p=0.007) (Figure 3A). Similarly, TNF-α production by TRM CD8+ cells was only observed in 128 
the LAIV-vaccinated group, increased by median 3.1- (p=0.006) and 2.1- (p=0.004) fold 129 
change in LAIV/Spn- and LAIV Spn+ group, respectively (Figure 3B). 130 
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IFN-γ responses by lung CD8+ T cells post stimulation were confined in the LAIV group. 131 
Although, both LAIV/Spn- and LAIV/Spn+ groups had the same levels of induction (1.5-fold 132 
increase) in the proportion of IFN-γ producing CD8+ T cells post stimulation (Figure 3C), this 133 
effect was statistically significant only in the LAIV/Spn+ group due to the lower variance within 134 
the group (Figure 3C).  TIV and control groups had overall no increase in the proportion of 135 
IFN- producing CD8+ T post stimulation with influenza antigens. In addition, IFN- production 136 
by lung TRM CD8+ T cells was not significantly altered post stimulation in any of the groups 137 
(Figure 3D).  138 
Stimulation did not elicit production of IL-17A producing CD8+ T cells, except for IL-17A 139 
production by TRM CD8+ T cells in the Spn colonized group (2.6-fold increase, p = 0.008) 140 
(Supplemental Figure 4C-D).  141 
 142 
LAIV increases frequency of influenza-specific IFN- producing TCR-δ+ T cells in the 143 
lungs of non-colonized individuals 144 
TCR-δ cells, a subset of specialized innate-like T cells that can exert effector functions 145 
immediately upon activation, play an important role in pulmonary infection (30, 31). Therefore, 146 
we assessed whether TCR-δ responses to influenza antigens were induced following 147 
vaccination. Although no significant increase in TNF-α producing TCR-δ+ was observed in 148 
any of the groups (Figure 4A), the proportion of IFN- producing TCR-δ+ was significantly 149 
greater in LAIV/Spn- group (median 2.9- fold increase upon stimulation compared to the 150 
unstimulated condition, p=0.002, Figure 4B). None of the other vaccinated or unvaccinated 151 
groups showed a significant induction of IFN- production. Similar to the other T cell subsets, 152 
IL-17A producing TCR-δ+ cells did not significantly increase after stimulation with influenza 153 




Streptococcus pneumoniae colonization impairs nasal IgA induction following LAIV but 156 
does not alter responses to TIV 157 
In addition to cellular responses, we sought to assess humoral responses elicited by TIV 158 
and LAIV vaccination both systemically and at the mucosal sites (nasal and lung). In serum 159 
samples, IgG levels against influenza antigens were measured at baseline (prior to bacterial 160 
challenge and influenza immunization) and at Day 24 post vaccination. TIV induced a 5.9-fold 161 
increase (p < 0.0001) of influenza-specific IgG, while LAIV intranasal administration did not 162 
confer increase of sera IgG levels (Figure 5A). Prior colonization of the nasopharynx with Spn 163 
did not alter influenza-specific IgG levels induced in response to either vaccine (Figure 5B). 164 
To assess antibody responses at the nasal mucosa, we measured influenza-specific IgA 165 
and IgG levels in nasal wash samples at baseline and 24 days following influenza 166 
immunization and described the kinetics of influenza-specific IgM at baseline, D3, D6, D11 167 
and D24 in both vaccine groups.  TIV induced a median 2.2- and a 5.2-fold increase in 168 
influenza virus-specific IgA and IgG levels, respectively, 24 days post-vaccination (Figure 5C-169 
F). LAIV also elicited an IgA and IgG antibody response, though both (IgA median 1.3-fold 170 
increase and IgG median 1.4-fold increase) were lower compared to those induced by TIV 171 
(Figure 5C-F). In addition, TIV induced an earlier and stronger IgM response in nasal mucosa 172 
compared to LAIV. Median of influenza-specific IgM titres in nasal lavage were 1.71x, 2.74x 173 
and 1.94x higher compared to baseline levels at D6, D11 and D24,respectively, in the TIV 174 
group, whereas in LAIV group they differed statistically significant from baseline only at D24 175 
post vaccine administration (median 1.22-fold increase from baseline) (Supplemental Figure 176 
6A). 177 
LAIV-mediated immunogenicity at the nasal mucosa was also dependent on Spn 178 
colonization, as observed for the lung cellular responses. Experimentally-induced colonization 179 
of the nasopharynx with Spn affected IgA titres, but neither IgG nor IgM, in the LAIV group 180 
(Figure 5E-F and Supplemental Figure 6C). At day 24 post-vaccination, the LAIV/Spn- group 181 
had significantly greater levels of IgA to influenza circulating in the nasal lumen, compared to 182 
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the LAIV/Spn+ counterparts (LAIV/Spn- median= 1.69, IQR: 0.98-2.65 vs LAIV/Spn+ 183 
median=1 .24, IQR: 0.66-1.81) (p=0.02) (Figure 5E). Spn colonization did not alter humoral 184 
responses to influenza in the TIV group for any antibody isotype (Figure 5E-F and 185 
Supplemental Figure 6B).   186 
IgG but not IgA is induced by influenza vaccines in the lung, with LAIV-mediated 187 
responses being impaired by pneumococcal colonization 188 
Humoral responses in the lung following TIV or LAIV vaccination were assessed in 189 
bronchoalveolar lavage (BAL) samples collected between 26 to 46 days post influenza 190 
vaccination (Figure 6). Due to the single timepoint sampling of the lung, 20 unvaccinated 191 
subjects (10 Spn-colonized and 10 non-colonized) were used as a control group.  192 
Levels of IgA to influenza in the lung did not differ between TIV, LAIV and control groups 193 
(Figure 6A). In terms of IgG levels, TIV induced a high IgG response (median 5.8-fold increase 194 
compared to control) (p < 0.0001), whereas LAIV conferred a modest IgG induction (median 195 
1.6-fold change compared to control) (p=0.028) (Figure 6B). TIV elicited influenza-specific IgG 196 
levels were 3.7x greater than LAIV-induced responses in the pulmonary mucosa (Figure 6B). 197 
Despite the late time point post vaccination, IgM to influenza was detectable in the lung and 198 
higher titres were measured in the TIV (3.3- fold increase compare to control) (p=0.0003) than 199 
in LAIV vaccinated subjects (1.81- fold increase compared to control) (p=0.022)  200 
(Supplemental Figure 6D) 201 
IgA levels were not significantly increased in the lung by vaccination and therefore not 202 
affected by Spn colonization (Figure 6C). Similar to IgA, IgM responses in the lung did not 203 
differ between Spn-colonized and non-colonized subjects (Supplemental Figure 6E). 204 
However, Spn colonization affected IgG titres in the LAIV vaccinated group, but not in the TIV 205 
group. IgG to influenza was higher in LAIV/Spn- group compared to the control group (1.73-206 




TLR priming by S. pneumoniae and increased type I IFN gene expression profile early 209 
post nasal colonization establishment 210 
To identify molecular signatures associated with reduced LAIV-mediated immunogenicity 211 
and impaired inflammatory responses due to established pneumococcal nasopharyngeal 212 
colonization, we performed host RNA-sequencing on nasal cells at baseline, day -1 (before 213 
vaccination) and at days 3 and 6 post vaccination. Two days after the bacterial challenge but 214 
prior influenza vaccination, the LAIV/Spn+ group showed enrichment in genes related with 215 
TLR signalling, including TLR2, TLR4 and TLR9 (Figure 7). As expected, gene enrichment in 216 
TRL signalling was not observed in the LAIV/Spn- group at the same time point post 217 
inoculation. Additionally, the LAIV/ Spn+ group exhibited enrichment in genes of interferon 218 
α/β, interferon-γ signalling and RIG-I/MDA5 mediated induction of IFN-α/β pathways (Figure 219 
7). The upregulation of these pathways suggests that pneumococcal colonised volunteers had 220 
increased antiviral responses the day before the LAIV administration; a molecular profile that 221 
is likely to interfere with the influenza virus replication cycle in the nasopharynx.  222 
To further investigate this observation, influenza RNA was quantified in unconcentrated 223 
nasal washes collected at Day 3 post vaccination in the LAIV group.  Only ¼ of the LAIV 224 
vaccinated group had detectable levels of influenza viral RNA in the nose 3 days post 225 
vaccination, with no statistically significant differences in the levels of influenza viral RNA 226 
(Supplemental Figure 7A) or in the percentage of shedders (CT < 40) between the Spn 227 
colonised (23.1%, 9/39) and non-colonised (27.5%, 11/40) (Supplemental Table 1). As 228 
expected, levels of influenza-specific IgA, following LAIV vaccination, were greater (2.5-fold 229 
change) in the nasal mucosa of volunteers with detectable viral influenza replication 230 
(Supplemental Figure 7B). In contrast, raised influenza-specific IgG levels following 231 





We investigated the cellular and humoral immune responses elicited by TIV and LAIV, 235 
focusing on respiratory mucosa, and assessed whether colonization of the nasopharynx with 236 
S. pneumoniae influences vaccine immunogenicity. In agreement with previous studies (3), 237 
TIV vaccination induced high systemic and mucosal antibody responses, whereas LAIV 238 
elicited both mucosal (mainly IgA) influenza virus-specific antibodies and cell-mediated 239 
immune responses. Interestingly, experimentally-induced pneumococcal colonization of the 240 
nasopharynx impaired host immunity to LAIV but did not alter TIV-induced responses.  241 
Antecedent pneumococcal colonization was also associated with weakened acute nasal pro-242 
inflammatory responses post LAIV vaccination.  243 
In the lungs, LAIV-induced cellular responses were heightened and significantly 244 
increased from those induced by TIV. LAIV nasal administration led to increased levels of 245 
TNF-α and IFN-γ producing CD4+ T cells, including TRMs, as well as TNF-α producing CD8+ 246 
T cells, upon in vitro stimulation. Interestingly, we observed that influenza specific CD4+ T cell 247 
lung responses were more pronounced in individuals not colonized with Spn at the time of 248 
vaccination suggesting increased immunogenicity of LAIV in the absence of pneumococcal 249 
colonization. Similarly, there was a higher proportion of IFN-γ producing TCR-γδ+ T cells in 250 
the non-colonized LAIV recipients. Moreover, LAIV was associated with increased frequencies 251 
of lung regulatory T cells, but only in the absence of nasal Spn colonization. 252 
Humoral responses were highly induced by TIV, whereas LAIV conferred an overall 253 
modest antibody induction. Systemically, TIV elicited influenza virus-specific IgG responses, 254 
which were not observed in the LAIV vaccinated arm. In the nose, TIV conferred predominantly 255 
IgG induction, while LAIV was mainly associated with high levels of IgA. Colonization of the 256 
nasopharynx with S. pneumoniae at the time of LAIV administration impaired the induction of 257 
mucosal IgA to influenza in the nose and IgG in the lung.  The modulatory effect of S. 258 
pneumoniae on adaptive immune responses to influenza virus has been previously reported 259 
in a murine co-infection model, highlighting the importance of current pathogen exposure, 260 
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which can critically affect the generation of protective antiviral antibodies and subsequently 261 
reduce influenza vaccination efficacy (23).  262 
The protection provided by LAIV relies on a transient viral replication in the 263 
nasopharynx in order to induce sufficient antibody levels to influenza, which we observed with 264 
increased IgA induction in shedders compared to non-shedders. LAIV in adults, unlike 265 
children, does not confer superior protection compared to TIV (32). An explanation consistent 266 
with the hypothesis is that life-long accumulation of influenza immunity through natural 267 
exposure and previous vaccinations can prevent the nasal replication of the attenuated virus 268 
and shorten the viral replication cycle (33). Herein, 25.3% of young adults vaccinated with 269 
LAIV shed attenuated influenza virus (either influenza A or B), in contrast to the much higher 270 
shedding rates observed in 2 to 5 years old children in other studies (34). Taking under 271 
consideration virus neutralization by pre-existing antibodies against influenza due to life-time 272 
exposure or a shortened virus replication cycle (33), increased influenza shedding has to 273 
detected in  the LAIV cohort in the first two days after the vaccine administration. 274 
Consequently, LAIV may elicit less potent responses in adults compared to children, thus any 275 
extrapolation from findings in adults to children, the target population for this vaccine, must be 276 
done with caution.  277 
Children display high rates of Spn colonization (35, 36). Our finding that concurrent 278 
Spn colonization could inhibit LAIV-induced immune responses, is another variable that 279 
should be taken into account when evaluating LAIV efficacy. This phenomenon could explain 280 
the lack of LAIV efficacy reported in Senegal (37), as Spn colonization rates are higher in low-281 
income countries (38). The impaired LAIV-induced immunity during established Spn 282 
colonization was associated with a lack of a pro-inflammatory response in the nasal mucosa 283 
following LAIV vaccination. An explanation for this is that Spn colonization affects local 284 
immune and epithelial cell responses upon LAIV vaccination, which could diminish immune 285 
cells infiltration and antigen presenting cells (APC) activation, impacting on the downstream 286 
memory responses (39, 40). For instance, lack or reduced production of IFNs by activated 287 
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nasal cells post vaccination may impact on innate immune responses to LAIV, by impairing 288 
natural killer and macrophage activation in the nasal mucosa and potentially dendritic cells 289 
migration and differentiation. Such an impaired innate immune response would also be 290 
translated to reduced antigen presentation and subsequently affect the adaptive immune 291 
responses.  292 
It is also possible that Spn colonization interferes with the viral replication cycle (41, 293 
42), through stimulation of TLR signalling. A number of studies have reported the broad 294 
contribution of TLR2 to the antiviral interferon response by indirectly governing the production 295 
of IFNs induced by other Toll like receptors, as wells as downstream of the cytosolic Rig-I like 296 
receptors (43, 44). In an infant mouse influenza A - S. pneumoniae co-infection model, mice 297 
deficient for TLR2 showed decreased expression of IFN-α and higher viral titres than the 298 
wildtype animals, with this great viral burden to correlate with heightened inflammation (45). 299 
In our study, Spn colonised volunteers upregulated genes involved in TLR2 signalling, RIG-300 
I/MDA5 mediated induction of IFN-α/β and IFN-α/β pathways before exposure to LAIV and 301 
exhibited impaired inflammatory responses post vaccination. A strong induction of TLR and 302 
IFN signalling pathways by Spn colonization may result in quick viral sensing and resolution 303 
of viral infection. Despite these observations, any alteration of viral replication cycle mediated 304 
by Spn colonization was limited by the late time point of viral quantification at day 3 post LAIV 305 
administration. An alternative hypothesis of the curtailed viral shedding in the LAIV/Spn+ 306 
group would be the inhibitory effect of pneumococcal neuraminidases, particularly NanA, on 307 
influenza virus attachment to the epithelium, as shown in an infant mouse model of S. 308 
pneumoniae-IAV coinfection model (46). In light of these observations, it would also be 309 
interesting to investigate to what extent symptoms and inflammation caused by wild type 310 
influenza viruses are altered by concurrent Spn colonization in humans.  311 
Ideally, an effective and broadly protective influenza vaccine should induce both 312 
humoral and cellular immunity. Whereas antibody responses to influenza show some degree 313 
of strain cross-reactivity (47, 48), they are insufficient to provide heterosubtypic, cross-strain 314 
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influenza protection (49, 50). Recent data from longitudinal cohort studies of naturally acquired 315 
infection have highlighted the potential of T-cells as key players in mediating heterosubtypic 316 
immunity in humans (51, 52). We observed that even in the absence of vaccination, healthy 317 
adults showed CD4+ T cell responses to influenza stimulation, which likely reflects their lifelong 318 
exposure to influenza viruses. The use of purified, adjuvanted influenza antigens (TIV) as the 319 
stimulus to measure cellular responses in vitro, would possibly lead to greater T cells 320 
responses. Our results demonstrated that LAIV induced influenza-specific cytokine-producing 321 
CD8+ and CD4+ T-cells, including TRM in the lung.  Such cells are important during influenza 322 
infection in protection of mucosal barrier tissues against pathogen challenge by producing 323 
chemokines for cell recruitment (53). It has been shown that TRM T cells provide superior 324 
protection to influenza infection when compared with circulating T cells (54). By seeding the 325 
lungs with these cells, it is possible to establish long-term heterosubtypic protection to 326 
influenza (55, 56).  327 
We have also demonstrated that, in volunteers not colonized by Spn, LAIV increased 328 
levels of Tregs in the lung compared to unvaccinated individuals. CD4+ Tregs contribute to 329 
homeostasis of the immune system, controlling infection by respiratory viruses and avoiding 330 
secondary bacterial infection (57). As a result of recurrent exposure to virus and bacteria, 331 
CD4+ Tregs increase in frequency with age (58). For this reason, our findings in adults might 332 
underestimate the effect of LAIV on frequency of Tregs in the lung of children. 333 
Although, LAIV and TIV mediated responses were assessed in the context of a 334 
randomised clinical trial, the study was limited by evaluation of a single pneumococcal 335 
serotype in healthy adults- likely to have neutralizing influenza antibodies and cross-reactive 336 
T cells. In addition, we evaluated pneumococcal and live-attenuated virus vaccine interaction 337 
during the early stages of pneumococcal colonization, when host responses to bacterial 338 
exposure may be higher compared to later time points. It is possible that this short-term 339 
window may not reflect accurately the overall effect of a colonization episode on LAIV immune 340 
responses. Any LAIV effect in children may be differential due to lower antibody titres to 341 
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influenza, higher natural rates of pneumococcal colonization and higher levels of inflammation 342 
compared to young adults (59). A future paediatric study, whereby colonization status would 343 
be assessed before LAIV administration and correlated with immune responses to the vaccine, 344 
would provide important insights into the magnitude of pneumococcal effect on vaccine 345 
immunogenicity in this population.  346 
In conclusion, using a controlled human model in which pneumococcal infection 347 
occurred at a known time relative to vaccination, we were able to highlight differences in 348 
immunogenicity between LAIV and TIV at relevant mucosal sites. Moreover, we identified S. 349 
pneumoniae colonization as an important variable in LAIV-induced immunity.  350 
METHODS 351 
Study Design 352 
Adult volunteers were enrolled in the parent LAIV clinical trial study (REC 14/NW/1460) 353 
(26). Exclusion criteria included: a prior history of influenza or pneumococcal vaccination; 354 
clinically confirmed pneumococcal disease in the preceding two years; pregnancy; close 355 
contact with individuals at increased risk for pneumococcal disease (children under 5, 356 
immunosuppressed, elderly); recent febrile illness; current or recent use of antibiotics or 357 
immune-modulating medication. Participants were inoculated with 80,000 CFU per nostril of 358 
serotype 6B as previously described (25). All volunteers received influenza vaccination 3 days 359 
post pneumococcal inoculation. LAIV group (n=80) received the live attenuated influenza 360 
vaccine (2016/2017 Fluenz Tetra, AstraZeneca, UK), whereas TIV group (n=90) received the 361 
tetravalent influenza vaccine, (2016/2017 Fluarix Tetra, GlaxoSmithKline, UK). These two 362 
vaccine formulations had the same combination of influenza A and influenza B strains. The 363 
overall carriage rates did not differ between LAIV and TIV group as measured by conventional 364 
microbiology (37/80 [46.3%] vs 45/90 [50.0%], respectively).  365 
For investigation of immune responses, samples of nasal wash, nasal lining fluid, nasal 366 
cells, bronchoalveolar lavage, serum were collected from volunteers at specific timepoints, 367 
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processed and frozen for future analysis (Supplementary Figure 1). For comparisons within 368 
the lung datasets, BAL fluid and lung lymphocytes from an unvaccinated EHPC group (n=20, 369 
10 Spn- and 10 Spn+) were used as a control. 370 
Detection of Spn colonization 371 
To detect bacteria in the nasopharynx, nasal wash samples plates were examined by 372 
classical microbiology for presence of Spn as previously described (60, 61). Colonized 373 
individuals were defined as anyone who had a positive nasal wash sample at any timepoint 374 
following inoculation. 375 
Bronchoalveolar lavage (BAL) analysis 376 
A bronchoalveolar lavage (BAL) sample was collected at the end of the trial, between 377 
26 to 46 days post-vaccination. Bronchoscopy was performed using topical anaesthesia and 378 
BAL was collected as described previously (62). Briefly, a total of 200 mL of warm 0.9% saline 379 
was instilled and retrieved from a sub-segmental bronchus of the right middle lobe by hand 380 
suction. The BAL was placed into sterile tubes on ice. BAL was processed as described (62). 381 
In short, the BAL sample was filtered to remove mucus and centrifuged at 400g for 10 minutes. 382 
BAL cells were re-suspended in RPMI with antibiotic mixture (Penicillin-Streptomycin-383 
Neomycin, Thermo-Fisher, Waltham, MA, USA). Cells were plated in a 24-well plate (Greiner 384 
Bio-One, Kremsmünster, Austria) to allow macrophages to adhere for 4 hours at 37oC, 5% 385 
CO2. Non-adherent BAL cells were collected, washed, centrifuged at 200g for 10min and 386 
resuspended in PRMI prior stimulation.  387 
Intracellular cytokine staining 388 
Non-adherent BAL cells were counted and incubated at 1x106 cells/mL in medium with 389 
RPMI, FBS (10% heat inactivated, Thermo-Fisher) and antibiotic mixture (Penicillin-390 
Streptomycin-Neomycin) at 37oC. Samples were stimulated with 1.2 g/mL influenza antigens 391 
(TIV, tetravalent influenza vaccine, 2016/2017) or left unstimulated as negative control, and 392 
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incubated for 2 hours. Then, 1000x diluted BD Golgiplug (BD Biosciences, San Jose, 393 
California, USA) was added and cells were cultured for an additional 16 hours. 394 
After 16 hours, the cells were washed with 3 mL of PBS, resuspended and stained with 395 
Violet Viability dye (LIVE/DEAD Fixable Dead Cell Stain kit, Invitrogen, UK). After 15 minutes, 396 
the cells were stained with the surface markers CD3-APCH7 (clone SK7), TCR-–PECy7 397 
(clone 11F2) from BD Biosciences (San Jose, California, USA), CD4–PerCP5.5 (clone SK3), 398 
CD8–AF700 (clone SK1), CD69–BV650 (clone FN5O), CD25-PE.TxsRed (clone M-A251), 399 
CD103–BV605 (clone Ber-ACT8), CD49a-APC (clone TS2/7) from Biolegend (San Diego, CA) 400 
and incubated for 15 minutes. Cells were fixed and permeabilized using the 401 
Foxp3/Transcription Factor Staining Buffer Set (eBiosciences, San Diego, CA) as per 402 
manufacturer’s instructions. Cells were then stained with intracellular markers FOXP3-FITC 403 
(clone 259D), IFN-γ-PE (clone 4S.B3), TNF-α–BV711 (cloneMAb11) Biolegend (San Diego, 404 
CA) and IL-10–BV786 (clone JES3-9D7) IL-17A–BV510 (clone N49-653) from BD 405 
Biosciences (San Jose, California, USA). After 30 minutes, samples were washed with 3 mL 406 
of PBS and resuspended in 200 µL of PBS and acquired on a BD LSR flow cytometer (Becton 407 
Dickinson, UK). Flow cytometry data was analysed using FlowJo cell analysis software version 408 
10 (FlowJo, LLC, Ashland, Ore). 409 
Quantitative reverse transcription-PCR (qRT-PCR). 410 
QRT-PCR was used to quantify nasal virus shedding on volunteers vaccinated with 411 
LAIV. RNA was isolated (RNeasykit; Qiagen) from nasal wash fluid, following generation of 412 
cDNA (high-capacity RT kit; Applied Biosystems) for use in quantitative PCR (SYBR Green 413 
PCR master mix; Applied Biosystems). Samples were tested using primers, probes and PCR 414 
assay conditions specific for human influenza virus A and B (63) .Results were analysed using 415 
the threshold cycle (2⫺ΔΔCT) method by comparison to GAPDH (glyceraldehyde-3-416 
phosphate dehydrogenase) transcription. 417 
Enzyme-linked immunosorbent assay (ELISA) 418 
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ELISA was used to quantify levels of IgG and IgA antibodies to influenza in the serum, 419 
as well as IgG, IgA and IgM in nasal wash and BAL supernatant of volunteers vaccinated with 420 
TIV or LAIV or unvaccinated. Pooled sera of 7 TIV vaccinated volunteers was heat-inactivated 421 
(at 56oC for 30 min) and used as standard in both total IgA and IgG to influenza ELISA. 422 
Antibody levels were expressed in arbitrary units relative to this standard curve. For IgG 423 
detection, an initial standard dilution of 1:4000 was used, while for IgA it was diluted 1:40.  424 
Briefly, 96-well plates (Nunc, Denmark) were coated with 100 µL of 0.2 µg/mL TIV in 425 
PBS overnight at room temperature. After the overnight incubation, plates were washed 426 
following blocking with 100 µL of PBS with 1% bovine serum albumin (BSA) for one hour at 427 
room temperature. Then, plates were washed, and samples were added in duplicates and 428 
incubated for 2 more hours at room temperature. Each wash consisted of washing the plate 429 
three times with PBS with 0.005% Tween 20 (Sigma, Germany). 430 
For detection of IgG , IgA and IgM, a 1:5000, 1:4000 and 1:2000 dilution of anti-human-431 
IgG (Sigma, A9544, Germany), anti-human-IgA (Sigma, A9669, Germany) and anti-human 432 
IgM (Sigma, A3437, Germany), respectively, was made using 0.1% BSA and 100 µL added 433 
to each well after washing and incubated at room temperature for 1 hour.  434 
Then, plates were washed and 100 µL of p-Nitrophenyl Phosphate (Sigma-Aldrich, 435 
Poole, U.K.) was added to the wells. The optical density of each well was measured at 405 436 
nm using a FLUOstar Omega ELISA microplate reader (BMG Labtech), the average blank 437 
corrected value was calculated for each sample and the data analysed using Omega Analysis 438 
(BMG Labtech). 439 
Luminex analysis of nasal lining fluid 440 
Nasal lining fluid was collected using nasosorption filters as previously described (64) and 441 
stored at -80oC until analysis. Prior to analysis, cytokines were eluted from stored filters using 442 
100μl of assay diluent buffer (ThermoFisher) by centrifugation. The eluate was cleared by 443 
further centrifugation at 16,000g for 10 min. Samples were and acquired on a LX200 using a 444 
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30-plex magnetic human Luminex cytokine kit (ThermoFisher) and results were analysed with 445 
xPonent3.1 software following manufacturer’s instructions. Samples were analysed in 446 
duplicates and cytokines with a CV>25% for a given sample were excluded from further 447 
analysis. 448 
RNA extraction and sequencing 449 
Nasal cells were collected in RNALater (ThermoFisher) at -80oC until extraction. RNA 450 
extraction was performed using the RNEasy micro kit (Qiagen) with on column DNA digestion. 451 
Extracted RNA was quantified using a Qubit™ (ThermoFisher). Sample integrity assessment 452 
(Bioanalyzer, Agilent), library preparation and RNA-sequencing (Illumina Hiseq4000, 20M 453 
reads, 100 paired-end reads) were performed at the Beijing Genome Institute (China). 454 
RNA sequencing analysis 455 
Quality control of raw sequencing data was done using fastQC. Mapping to a human reference 456 
genome assembly (GRCh38) was done using STAR 2.5.0a (65). Read counts from the 457 
resulting BAM alignment files were obtained with featureCounts using a GTF gene annotation 458 
from the Ensembl database (66, 67). The R/Bioconductor package DESeq2 was used to 459 
identify differentially expressed genes among the samples, after removing absent features 460 
(zero counts) (68). Genes with an FDR value < 0.1 and an absolute fold change (FC) > 1.5 461 
(baseline-normalised values) were identified as differentially expressed. For each timepoint 462 
comparison, gene set enrichment analysis (GSEA) was performed using the fgsea R package. 463 
Genes with Ensembl IDs were transformed into Gene Symbols by the biomart package (69) 464 
and ordered by its log fold-change values. Pre-ranked genes and Reactome gene sets from 465 
Enrichr (70) were provided to fgsea, with remaining default parameters. To identify significant 466 
common pathways between all comparisons, pathways with a p-value below a threshold of 467 
0.05 for at least one comparison were selected and clustered based on the Normalized 468 
Enrichment Scores (NES) with hierarchical clustering. Correlation plots were generated to 469 
display the NES values using the corrplot package. 470 
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Statistical analysis 471 
All sampling, processing and data analysis were performed while blinded to vaccination group 472 
to not bias results. Non-parametric tests were used for statistical analysis where number of 473 
samples were insufficient for a normal distribution of results. Statistics were calculated in 474 
GraphPad prism version 6.0 and 7.0 for Windows (GraphPad Software, California USA) and 475 
R Statistical Software (R Foundation for Statistical Computing). Differences were considered 476 
statically significant if p ≤ 0.05. Benjamini-Hochberg multiple correction was performed in R 477 
on both 30-plex cytokine data and RNAseq data analysis.  478 
Study approval 479 
Ethical approval was given by the North West-Liverpool East Research Ethics Committee 480 
(REC) reference number 14/NW/1460. The trial was registered on EudraCT, Protocol 2014-481 
004634-26 (NCT ID: NCT03502291). All volunteers gave written informed consent and 482 
research was conducted in compliance with all relevant ethical regulations. BAL samples of 483 
the control (non-vaccinated cohort) were collected at part of separate EHPC clinical trial (REC 484 
15/NW/0931). 485 
Data availability 486 
Raw RNA sequencing data have been deposited in the Gene Expression Omnibus repository, 487 
accession number GSE164649. All other underlying data are provided in the manuscript. 488 
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Figure 1. Pneumococcal colonization prevents an acute nasal LAIV-induced pro-
inflammatory response. (A) Study design. Healthy adults (n= 170) aged 18 to 48 years were 
recruited and participated in a randomized, controlled clinical trial. Subjects were screened 8 
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days pre-vaccination (baseline), followed by challenge with live S. pneumoniae 3 days before 
vaccination against influenza (D-3).  Then they received either live attenuated influenza 
vaccine (LAIV) or tetravalent influenza vaccine (TIV) at day 0 (D0). Serum samples were 
collected at Baseline (D-8) and D24. Nasal wash samples were collected from all volunteers 
at D-8, D-1, D3, D6, and D24, but only for the pneumococcal colonized at D11 and D18. Nasal 
fluid and cells were collected at D-8, D-1, D3 and D6, plus at D24 for nasal fluid only. A 
bronchoalveolar lavage (BAL) sample was collected at the end of the trial, between 26 to 46 
days post-vaccination. (B-E) Levels of 30 cytokines were measured in nasal fluid at baseline, 
1 day before vaccination (D-1), and 3, 6 and 24 days after vaccination for LAIV/Spn- (LAIV 
vaccinated/non-colonized, n=15), LAIV/Spn+ (LAIV vaccinated/colonized, n=15), TIV/Spn- 
(TIV vaccinated/non-colonized, n=16) and TIV/Spn+ (TIV vaccinated/colonized, n=14). (B&D) 
Samples were clustered based on fold-change levels to baseline using t-distributed stochastic 
neighbour embedding (t-sne) for LAIV (blue) or TIV (orange). R and P values shown for 
significant time points based on analysis of similarity (anosim) including fold-changes for all 
30 cytokines. (C) Heatmap showing median log2 fold change (log2FC) to baseline levels at 
each of the 4 timepoints after LAIV or TIV administration, irrespectively colonization status.  
Red colour indicates upregulation and blue downregulation in cytokines levels from baseline. 
(E) Heatmap showing median log2FC to baseline levels at each of the 4 timepoints for the 4 
experimental groups, based on stratification by vaccine and colonization status. Statistical 
comparisons were applied against the baseline sample for each time point in every group 
independently **p < 0.01, *p < 0.05 by Wilcoxon paired test, followed by Benjamini-Hochberg 







Figure 2. LAIV increases frequency of influenza-specific TNF- and IFN--producing CD4+ and tissue 
resident memory (TRM) CD4+ T cells in the lung. Frequencies of cytokine-producing CD4+ and TRM 
CD4+ T cells were measured in human BAL samples by intracellular staining flow cytometry analysis 
with and without (mock) in vitro influenza antigen stimulation. Volunteers were divided by vaccine 
and colonization status in TIV/Spn- (n=6), TIV/Spn+ (n=8), LAIV/Spn- (n=10), LAIV/Spn+ (n=9), 
unvaccinated (n=8, 3 Spn- and 5 Spn+) group. (A) Production of TNF-α by total CD4+ T cells in each 
group [paired unstimulated (mock) and stimulated condition (flu)]. (B) influenza-specific production 
of TNF-α by total CD4+ T cells (Difference between influenza-stimulated and unstimulated) in each 
group. (C) Production of TNF-α by CD4+ CD69+ T-cells in each group. (D) Production of influenza-
specific TNF-α by CD4+ CD69+ T-cells in each group. (E) Production of IFN- ɣ by total CD4+ T cells in each 
group. (F) Production of influenza-specific IFN-γ by CD4+ T-cells in each group. (G) Production of IFN-
γ by CD4+ CD69+ T-cells and (H) influenza-specific IFN-γ by CD4+ CD69+ T-cells in each group. Each 
individual dot represents a single volunteer and the conditions from one individual are connected. 
Medians with IQR are depicted for influenza-specific responses (panels B, D, F and H). *p < 0.05, **p 
< 0.01 by Wilcoxon test for comparisons within the same group and by Mann-Whitney test for 





Figure 3. LAIV increases frequency of influenza-specific TNF- producing CD8+ and tissue-resident 
memory CD8+ T cells in the lungs. Frequencies of cytokine-producing CD8+ T cells were measured in 
human BAL samples by intracellular staining flow cytometry analysis following stimulation with 
influenza antigens or non-stimulation (mock) in each group. Volunteers were divided by vaccine and 
colonization status in TIV/Spn- (n=6), TIV/Spn+ (n=8), LAIV/Spn- (n=10), LAIV/Spn+ (n=9) and 
unvaccinated (n=8, 3 Spn- and 5 Spn+) group. Production of TNF-α by (A) total CD8+ T-cells and (B) 
TRM CD8+ T-cells in each group (paired unstimulated [mock] and stimulated condition [Flu]). 
Production of IFN- ɣ production by (C) total CD8+ T-cells and (D) TRM CD8+ T-cells in each group. Each 
individual dot represents a single volunteer and the conditions per individual are connected. *p < 0.05, 





Figure 4. LAIV increases frequency of IFN- producing influenza-specific TCR-δ+ in the lungs of Spn 
non-colonized individuals. Frequency of cytokine-producing TCR-δ+ T cells was measured in human 
BAL samples by intracellular staining flow cytometry analysis after in vitro stimulation with influenza 
antigens or non-stimulation (mock). Volunteers were divided by vaccine and colonization status in 
TIV/Spn- (n=6), TIV/Spn+ (n=8), LAIV/Spn- (n=10), LAIV/Spn+ (n=9) and unvaccinated (n=8, 3 Spn- and 
5 Spn+) group. Production of (Α) TNF-α, (Β) IFN-γ and (C) IL-17A by lung TCR-γδ T cells. Individual dot 






Figure 5. LAIV vaccination increases levels of antibody to influenza in serum and nasal wash, with 
impaired nasal production caused by Streptococcus pneumoniae colonization. (A) IgG titres to 
influenza, measured by ELISA, in serum of LAIV (n=36) and TIV (n=36) vaccinated subjects at baseline 
(8 days pre-vaccination) and D24 (24 days post-vaccination). (B) Fold change (D24/Baseline) of paired 
IgG titres to influenza in serum following TIV or LAIV vaccination. TIV/Spn- (n=20), TIV/Spn+ (n=16), 
LAIV/Spn- (n=18); LAIV/Spn+ (n=18). (C) IgA and (D) IgG titres to influenza measured by ELISA in nasal 
34 
 
wash of TIV (n=40) and LAIV (n=80) vaccinated subjects at baseline (8 days pre-vaccination) and D24 
(24 days post-vaccination). (E) Fold change (D24/Baseline) of paired IgA and (F) IgG titres to influenza 
in nasal wash following vaccination with TIV/Spn- (n=21), TIV/Spn+ (n=19), LAIV/ Spn- (n=37), LAIV/ 
Spn+ (n=43). Medians with IQR are shown. *p <0.05, ***p < 0.001, ****p < 0.0001 by Wilcoxon test 













Figure 6. IgG but not IgA is induced by influenza vaccines in the lung, with LAIV responses being 
reduced during Spn colonization. (A)-(B) IgA and IgG titres to influenza for TIV (n=20), LAIV (n=19) 
vaccinated subjects and unvaccinated (n=20) was measured by ELISA in BAL fluid.  (C)-(D) IgA and IgG 
titres grouped based on vaccination and colonization status, as TIV/Spn- (n=9), TIV/Spn+ (n=11), 
LAIV/Spn- (n=11), LAIV/ Spn+ (n=8), unvaccinated (n=20). Medians with IQR are shown. *p <0.05, ** 
p<0.01, **** p < 0.0001 by Wilcoxon test for comparisons within the same group and by Mann-





Figure 7. TLR priming by S. pneumoniae and increased type I IFN gene expression profile early post 
nasal colonization. Selected pathways after Gene Set Enrichment Analysis (GSEA) for LAIV/Spn- (n=11) 
and LAIV/Spn+ (n= 9) groups at D-1, D3 and D6 in relation to LAIV administration applied on log2-fold 
changes (baseline/pre-Spn inoculation-normalised values). Normalised Enrichment Score (NES) is 
presented in gradient colour. Red shades indicate pathways over-presented, whereas blue shades 
depict the under-presented pathways at each time point in relation to baseline (prior pneumococcal 
inoculation). *p<0.05 by Wilcoxon paired test corrected by multiple-comparison testing (Benjamini-
Hochberg). 
 
